Trial Profile
A Study Assessing The Effect Of Low-Dose Rituximab, Double-Filtration Plasmapheresis (DFPP) And Prophylactic Antibiotic Therapy On Survival Outcomes And Infectious Complications In Patients Undergoing ABO-Incompatible Living Donor Liver Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Liver transplant rejection
- Focus Therapeutic Use
- 12 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress.